Cite
HARVARD Citation
Eggermont, A. et al. (2019). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European journal of cancer. pp. 148-157. [Online].